Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial.

ABSTRACT:

Purpose

The time spent in pursuing treatments for advanced cancer can be substantial. We have previously proposed a pragmatic and patient-centered metric of these time costs-which we term time toxicity-as any day with physical health care system contact. This includes outpatient visits (eg, bloodwork, scans, etc), emergency department visits, and overnight stays in a health care facility. Herein, we sought to assess time toxicity in a completed randomized controlled trial (RCT).

Methods

We conducted a secondary analysis of the Canadian Cancer Trials Group CO.17 RCT that evaluated weekly cetuximab infusions versus supportive care alone in 572 patients with advanced colorectal cancer. Initial results reported a 6-week improvement in median overall survival (OS) with cetuximab

SUBMITTER: Gupta A 

PROVIDER: S-EPMC10337749 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature